Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Paul McCracken
AddedFeb 13, 2024
UpdatedMay 31, 2026
Paul McCracken

Paul McCracken

Board Member, Insitro

CrunchbaseLinkedInThe Org

Paul McCracken's Career

Insitro
Insitro

South San Francisco, CA, US

Board Member· Board
Asimov
Asimov

Boston, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Paul McCracken's Career

Insitro
Insitro
Series C$643M2952018South San Francisco, CA, US
Board Member· Board

Leadership at Insitro

Vijay PandeVijay PandeBoard Member
Roger PerlmutterRoger PerlmutterBoard Member
Daphne KollerDaphne KollerCEO
Daphne KollerDaphne KollerCEO
Robert NelsenRobert NelsenBoard Member
Asimov
Asimov
Series B$205M1112017Boston, MA, US
Board Member· Board

Leadership at Asimov

Raja SrinivasRaja SrinivasCo-Founder
Alec NielsenAlec NielsenCo-Founder
Jorge CondeJorge CondeBoard Member
Christopher VoigtChristopher VoigtCo-Founder
Douglas DensmoreDouglas DensmoreCo-Founder

Similar to Asimov

AI ProteinsAI ProteinsBoston, MA, USProtein Therapeuticsest. 2021AI ProteinsBoston, MA, US · est. 2021

AI Proteins: A biotech firm specializing in the design and engineering of synthetic mini protein therapeutics.

Series B · $18.2M44
AbsciAbsciVancouver, WA, USDrug Developmentest. 2011AbsciVancouver, WA, US · est. 2011

AbSci Corp: A US-based synthetic biology firm streamlining biologic drug discovery and development.

Public · $237.9M193
Think BioscienceThink BioscienceBoulder, CO, USMedicinesest. 2019Think BioscienceBoulder, CO, US · est. 2019

Think Bioscience innovates synthetic biology, designing superior medicines using living systems.

Seed · $17.3M26
AsimicAAsimicAWyoming, MI, USMicrobial Biotechest. 2018AsimicAWyoming, MI, US · est. 2018

AsimicA: Innovating novel technologies for enhanced production in Microbial Biosynthetic Factories.

Seed · $250k7

Paul McCracken's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Paul McCracken

Saeid AkhtariSaeid AkhtariFounder · HBM GenomicsPaul J ClancyPaul J ClancyBoard Member · IncyteElliot ElsonElliot ElsonBoard Member · InvivosciencesRoger A. FieldingRoger A. FieldingBoard Member · InsideTrackerSteven TuckerSteven TuckerBoard Member · InsideTrackerLenny GuarenteLenny GuarenteFounder · Elixir Pharmaceuticals